Search Results 451-460 of 16282 for GLP-1 agonist

1. Neurofibromatosis type 1 - Doctors and departments - Mayo Clinic

   Research. Mayo Clinic researchers study genetics, causes and new treatments for people with neurofibromatosis type 1. Research is conducted by Mayo Clinic ...

2. A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC - Mayo Clinic

   This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

3. Christina A. von Roemeling1, Laura Marlow1, Robert C. Smallridge2, John A. Copland1

   Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin ...

4. Amphetamine (oral route) - Side effects & dosage - Mayo Clinic

   If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Abiraterone Acetate; Abiraterone ...

5. Interferon beta-1a (intramuscular route, subcutaneous route) - Side effects & dosage - Mayo Clinic

   If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Zidovudine. Other Interactions.

6. Insulin and Insulin Pulses on Fasting Glucagon Secretion and on Glucose Metabolism in Subjects Without Type 2 Diabetes - Mayo Clinic

   Participation eligibility · Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects ...

7. Darbepoetin alfa (injection route) - Mayo Clinic

   You might not use all of the medicine in each vial (glass container) or prefilled syringe. Use each vial or syringe only one time. Do not save an open vial or ...

8. Glofitamab-gxbm (intravenous route) - Side effects & uses - Mayo Clinic

   Your doctor may also give you other cancer medicine (eg, obinutuzumab) on Day 1 of cycle 1 before starting treatment with this medicine. Back to top ...

9. Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1 - Mayo Clinic

   Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1 · Overview · Participation eligibility · Participating Mayo Clinic locations · More ...

10. Galcanezumab-gnlm (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Use each prefilled syringe and pen only one time. Do not save an open syringe or pen. Dosing. The dose of this medicine will be different for different patients ...